Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study
Main finding · Diabetic nephropathyResult — go to the resultAdjusted hazard ratio 0.94 95% CI 0.85–1.04Authors' conclusion
We did not find an association between use of a long-acting insulin analogue, compared with use of NPH insulin, and the risk of diabetic nephropathy among patients with T2D.
Study context
- Population
- Patients with T2D, UK Clinical Practice Research Datalink AURUM
- Exposure
- Long-acting insulin analogues vs neutral protamine Hagedorn (NPH) insulin
- Outcome
- Incident diabetic nephropathy
Methodological detailsactive-comparator, new user design, inverse probability of treatment weighting
- Active-comparator, new user design
- Inverse probability of treatment weighting
Main finding
Diabetic nephropathy
Adjusted hazard ratio
0.94
95% CI 0.85–1.04
By group
Long-acting insulin analogues
16.3 per 1000 person-years
95% CI 15.3–17.4
NPH insulin
17.5 per 1000 person-years
95% CI 16.3–18.8
Long-acting insulin analoguesvs NPH insulin
aHR 0.94 (95% CI 0.85–1.04)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aHR (95% CI) | |
|---|---|---|
| CKD | 0.91 (0.88–0.94) | |
| End-stage renal disease | 0.78 (0.46–1.32) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study. Diabetes Obes Metab. Published 12 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →